Open AccessSuccessful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney–liver transplantation
Author(s) -
Delabaudière Cyrielle,
Lavayssière Laurence,
Dörr Gaëlle,
Muscari Fabrice,
Danjoux Marie,
Sallusto Federico,
Peron Jean Marie,
Bureau Christophe,
Rostaing Lionel,
Izopet Jacques,
Kamar Nassim
Publication year - 2015
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/tri.12428
Subject(s) - medicine , ribavirin , sofosbuvir , pegylated interferon , liver transplantation , gastroenterology , hepatitis c , combination therapy , hepatitis c virus , kidney transplantation , hepatology , interferon , transplantation , immunology , virus
Summary Fibrosing cholestatic hepatitis ( FCH ) is a classical but rare and severe form of recurrent hepatitis C virus ( HCV ) after liver transplantation. Classical anti‐ HCV therapy, that is pegylated‐interferon (peg‐interferon) and ribavirin, has been shown to have limited efficacy in treating FCH . Herein, we report on the first case of successful use of peg‐interferon, ribavirin, plus sofosbuvir to treat HCV ‐induced FCH in a combined liver–kidney transplant patient. Antiviral therapy was given for 24 weeks. HCV clearance occurred within 4 weeks after starting therapy and was maintained until 4 weeks after the end of therapy. Antiviral tolerance was good. We conclude that the use of sofosbuvir‐based anti‐ HCV therapy can be successfully used to treat FCH after a liver or combined kidney–liver transplantation.